Status:
UNKNOWN
Oral Glyceryl Triacetate (GTA) in Newborns With Canavan
Lead Sponsor:
Shaare Zedek Medical Center
Conditions:
Canavan Disease
Eligibility:
All Genders
Up to 18 years
Phase:
NA
Brief Summary
Canavan disease is caused by Aspartoacylase deficiency. There is no treatment for the disease, but there is a food additive that includes acetate . We suggest an early treatment with acetate and a neu...
Eligibility Criteria
Inclusion
- clinical diagnosis of Canavan disease
Exclusion
- Age above 18 months
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT00724802
Start Date
March 1 2008
Last Update
June 21 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shaare Zedek Medical Center
Jerusalem, Israel, 91031